With respect to GLP-1RAs, liraglutide and semaglutide have demonstrated a reduction in the risk of major adverse cardiovascular events (MACE) [16, 17], and, while yet not published, early reports for dulaglutide indicate CV benefits in patients with a wide range of CV risk [18]
Fiber is much more complicated than people usually give it credit for, but its mostly the soluble and fermentable fibers that seem to promote satiety, typically in pretty high doses (12+ grams)
Patients already on spironolactone for hypertension management face a small risk of excessive blood pressure reduction if semaglutide dosing escalates too rapidly
However, its effects on recovery, inflammation reduction, and overall health may indirectly support hormone balance, including testosterone
Historical cohorts of decompensated cirrhosis patients with similar MELD-3 scores typically experience 20%30% annual mortality
The peptide research community has known this for decades, but the guidance rarely makes it into consumer-facing storage instructions
